Clinical outcomes after switching from omalizumab to anti-IL-5/IL-5R biologics in severe asthma: a retrospective cohort study

Abstract Background Severe asthma (SA) is a heterogeneous disease composed of various clinical phenotypes, and criteria for selecting the most appropriate biological agent remain unclear. Therefore, when optimal control cannot be achieved with the initial biological therapy, switching between biolog...

詳細記述

書誌詳細

主要な著者:	Fatma Arzu Akkuş, Fatih Çölkesen, Tuğba Önalan, Mehmet Emin Gerek, Mehmet Kılınç, Şevket Arslan
フォーマット:	Artigo
言語:	Inglês
出版事項:	BMC 2025-11-01
シリーズ:	BMC Pulmonary Medicine
主題:	Benralizumab Biologic therapy Eosinophils Mepolizumab Omalizumab Severe asthma
オンライン･アクセス:	https://doi.org/10.1186/s12890-025-04044-7
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!